The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHOC 2022 | The importance of analyzing cytogenetic risk in patients with AML undergoing haploidentical SCT
In this video, Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses the importance of analyzing cytogenetic risk in patients with acute myeloid leukemia (AML) undergoing haploidentical stem cell transplantation (SCT). Prof. Nagler first gives an overview of the biology behind haploidentical SCT, and then goes on to explain the role of cytogenetics as an important prognostic factor in patients undergoing transplantation. This interview took place at the XIII Eurasian Hematology-Oncology Congress (EHOC) held in Istanbul, Turkey.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
